|Cell Line Name:||EMT6/AR10.0|
|Keywords:||Mouse mammary, drug-resistant|
|Cell Line Description:||The drug resistant cell line EMT6/AR10.0 was derived from the mouse mammary tumour cell line EMT6/P (ECACC catalogue no. 96042344) by continuous growth in increasing concentrations of doxorubicin. It was reported to show reduced intracellular drug accumulation and hyperexpression of P-glycoprotein. It is recommended to culture the cells without drug after resuscitation until the first passage.|
|Subculture Routine:||Split sub-confluent cultures (70-80%) 1:3 to 1:6 using 0.25% trypsin or trypsin/EDTA; 5%CO2; 37ºC; resuscitate in drug-free media, add doxorubicin after first passage|
|Culture Medium:||MEM(EBSS) + 2mM Glutamine + 1% Non Essential Amino Acids (NEAA)+ 10.0µg/ml doxorubicin + 10% Foetal Bovine Serum (FBS).|
|Depositor:||Dr P Twentyman, Dr. K. Wright, UKCCR, PO Box 123, Lincolns Inn Fields, London WC2A 3PX|
|References:||J Natl Cancer Inst 1989;81:1588|
|Additional Bibliography:||Not specified|
|Patents:||None specified by Depositor|
|Research Council Deposit:||Yes|
The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.
Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.